Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

APX001: A New Antifungal with Activity Against Candida auris

OCT 16, 2017 | CONTAGION® EDITORIAL STAFF


Ciara Kennedy, PhD, president and CEO of Amplyx Pharmaceuticals, Inc, explains that by targeting an enzyme with the fungal cell, APX001 is able to inhibit the formation of the fungal cell wall, thereby decreasing the virulence, pathogenicity, and biofilm-producing capabilities of the fungus. Data from phase 1 studies are promising for this new antifungal to be able to be administered in both intravenous and oral forms, providing physicians with a new opportunity for continuum of care, using the same mechanism of action.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.